These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 1234504)

  • 1. A general equation for the ratio of the areas below the blood or plasma concentration time-curves following intravenous and oral drug administration and its application to inter-subject variations in drug elimination.
    Vaughan DP; Trainor A
    Br J Clin Pharmacol; 1975 Jun; 2(3):239-50. PubMed ID: 1234504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model independent derivation of general equations for the "first-pass" effect and extra-hepatic drug elimination.
    Vaughan
    Eur J Clin Pharmacol; 1977; 11(1):57-64. PubMed ID: 832659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A general model of metabolite kinetics following intravenous and oral administration of the parent drug.
    Weiss M
    Biopharm Drug Dispos; 1988; 9(2):159-76. PubMed ID: 3370305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A convenient method for estimating the quantity of drug eliminated by the routes other than hepatic metabolism and renal excretion and the fraction of drug that reaches the "first pass" after oral administration.
    Berezhkovskiy LM
    J Pharm Sci; 2006 Apr; 95(4):828-33. PubMed ID: 16489605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-pass elimination. Basic concepts and clinical consequences.
    Pond SM; Tozer TN
    Clin Pharmacokinet; 1984; 9(1):1-25. PubMed ID: 6362950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Route of administration and drug metabolism.
    Gibaldi M; Feldman S
    Eur J Pharmacol; 1972 Sep; 19(3):323-9. PubMed ID: 4640856
    [No Abstract]   [Full Text] [Related]  

  • 7. Estimation of area under the curve for drugs subject to enterohepatic cycling.
    Shepard TA; Reuning RH; Aarons LJ
    J Pharmacokinet Biopharm; 1985 Dec; 13(6):589-608. PubMed ID: 3834073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of drug kinetics in blood on the calculation of oral bioavailability in linear pharmacokinetics: the traditional equation may considerably overestimate the true value.
    Berezhkovskiy LM
    J Pharm Sci; 2006 Apr; 95(4):834-48. PubMed ID: 16493592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug metabolite concentration-time profiles: influence of route of drug administration.
    Houston JB; Taylor G
    Br J Clin Pharmacol; 1984 Apr; 17(4):385-94. PubMed ID: 6721984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ratio of first to zeroth moments of the plasma profile of an oral drug undergoing first-pass and linear reversible metabolism.
    Cheng H
    Biopharm Drug Dispos; 1995 Dec; 16(9):791-6. PubMed ID: 8580402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presystemic elimination of drugs: theoretical considerations for quantifying the relative contribution of gut and liver.
    Minchin RF; Ilett KF
    J Pharm Sci; 1982 Apr; 71(4):458-60. PubMed ID: 7086660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel method for bioavailability assessment.
    Kwan KC; Till AE
    J Pharm Sci; 1973 Sep; 62(9):1494-7. PubMed ID: 4743100
    [No Abstract]   [Full Text] [Related]  

  • 13. The simulation of the elimination process for a substance injected into the blood stream.
    Hallberg D; McLean A
    Acta Med Scand; 1973; 194(3):173-9. PubMed ID: 4746525
    [No Abstract]   [Full Text] [Related]  

  • 14. Kinetics of sequential metabolism. Contribution of parallel, primary metabolic pathways to the formation of a common, secondary metabolite.
    Pang KS
    Drug Metab Dispos; 1995 Feb; 23(2):166-77. PubMed ID: 7736907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Route of administration and drug disposition.
    Gibaldi M; Perrier D
    Drug Metab Rev; 1974; 3(2):185-99. PubMed ID: 4607867
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacokinetic interpretation of data gathered during therapeutic drug monitoring.
    Dvorchik BH; Vesell ES
    Clin Chem; 1976 Jun; 22(6):868-78. PubMed ID: 776451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating reduced availability due to first pass elimination from relative total clearance and renal clearance.
    Brockmeier D
    Eur J Clin Pharmacol; 1988; 35(4):397-400. PubMed ID: 3197748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An overview of the analysis and interpretation of bioavailability studies in man.
    Wagner JG
    Arzneimittelforschung; 1976; 26(1A):105-8. PubMed ID: 947190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elementary pharmacokinetics in clinical practice. 3: Practical pharmacokinetic applications.
    Paxton JW
    N Z Med J; 1981 Nov; 94(696):381-4. PubMed ID: 6948206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Commentary: a physiological approach to hepatic drug clearance.
    Wilkinson GR; Shand DG
    Clin Pharmacol Ther; 1975 Oct; 18(4):377-90. PubMed ID: 1164821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.